Aurobindo Pharma’s Q1 Surge: 25% Net Profit Rise Counters Single USFDA Observation

Aurobindo Pharma’s Q1 Surge: 25% Net Profit Rise Counters Single USFDA Observation​

Aurobindo Pharma shares remain under scrutiny amidst operational checks following the receipt of a single observation from the United States Food and Drug Administration (USFDA) regarding its Telangana facility. The market continues to monitor how this compliance issue impacts the company, especially given recent robust financial disclosures.

The inspection conducted by USFDA at AuroPeptides, the manufacturer of Peptide APIs located in Telangana, concluded with only one observation. This check took place between August 17 and August 21, 2026. The management has confirmed that this specific observation relates to facility and equipment maintenance.

USFDA Observation and Compliance Status​

The company stated that the observed matter does not concern data integrity or any critical GMP compliance issues. Aurobindo has already initiated corrective actions during the inspection process. A formal response detailing these steps will be submitted within the stipulated timeline, providing clarity on the resolution.

This inspection adds context to the previous regulatory scrutiny, as the company had recently received an Establishment Inspection Report (EIR) for its Raleigh Plant in North Carolina, USA. That facility was classified by USFDA as "Voluntary Action Indicated" (VAI).

Q1 Financials Drive Market Resilience​

In strong contrast to the compliance focus, Aurobindo Pharma delivered impressive results in its first quarter of FY27. The company reported a 25.2% year-on-year rise in net profit, achieving Rs 1,032 crore, significantly up from the Rs 824 crore reported a year earlier.

Revenue also saw a healthy increase of 16.3% year-on-year, reaching Rs 9,150.3 crore. This performance successfully exceeded the CNBC-TV18 poll estimate, which stood at Rs 9,030 crore for the quarter.

EBITDA Growth and Margin Improvement​

The company’s operational efficiency shone through as EBITDA grew by 17.3% compared to the previous year. Aurobindo achieved an EBITDA of Rs 1,881 crore, surpassing the estimate provided by CNBC-TV18 at Rs 1,848 crore. This positive trend was supported by an improved EBITDA margin, which climbed to 21% from 20% in the corresponding period last year.